Bilateral, contralateral multifocal IOLs yield similar distance, intermediate visual acuity

Bilateral implantation of one multifocal IOL power was non-inferior to contralateral implantation of different multifocal IOL powers in improving distance and intermediate visual acuity, according to a study. However, contralateral implantation yielded superior near vision.“Contralateral implantation might be more beneficial for reading than bilateral implantation. Thus, patients demanding spectacle independence when reading would benefit from contralateral implantation,” corresponding author Soraya M.R. Jonker, MD, and colleagues said in the study, published in the Journal of Cataract and Refractive Surgery.

Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that clinical data from the company’s Phase 2a study of its lead candidate, AKB-9778, for the treatment of patients with DME, have been published in an article titled “Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression,” which is currently available online